Dermapy · Psoriasis Remote Patient Monitoring

A psoriasis RPM model built for scientific evidence and reimbursement.

Dermapy supports psoriasis follow-up with structured ePROMs, patient-submitted photos, and clinician-led review between visits. The primary objective is not just digital convenience, but a scientifically credible path toward payer adoption and reimbursement.

View published studies See research programme

Clinician-led by design. Dermapy improves visibility between appointments; treatment decisions remain with healthcare professionals.

Scientific and reimbursement focus

The psoriasis programme is designed to answer the questions that matter to researchers, payers, and health systems: medical effectiveness, usability, feasibility, cost impact, and implementation fit.

Psoriasis-specific follow-upStructured remote follow-up using ePROMs relevant to psoriasis, including DLQI, symptoms and EARP, with optional clinical photos.

Real-world care modelUsed across specialist and primary care, rather than as a stand-alone pilot disconnected from clinical workflow.

HTA-oriented evidenceFocus on clinical equivalence, user experience, feasibility, average costs, and cost-effectiveness.

Reimbursement pathwayEvidence generation is structured to support discussions with payers rather than only product marketing.

Core monitoring logic

Symptoms and quality-of-life changes are captured remotely, enriched with photos, reviewed by clinicians, and used to support earlier follow-up or treatment adjustment when clinically appropriate.

2×faster access than a traditional waiting list in the specialist-care implementation

68%reported improved disease management

76%reported quality of life improved or remained stable

86.6patient-rated system usability score out of 100 in specialist-care implementation

Why psoriasis

Psoriasis is chronic, relapsing, and difficult to manage only through episodic visits.

Psoriasis is a life-long inflammatory disease with fluctuating activity and a broad comorbidity burden. This makes it especially suitable for a structured remote monitoring model that can capture change between appointments.

Clinical rationale

80M

people worldwide are affected by psoriasis, underlining the need for scalable long-term management models.

15+

comorbidities are more likely than in the general population, reinforcing the importance of continuity and early response.

5 yrs

earlier mortality on average was highlighted in the presentation as part of the long-term disease burden.

Why remote monitoring fits

Psoriasis symptoms rise and fall over time. Conventional care often sees only snapshots at in-person appointments. Dermapy adds structured follow-up in the period between visits, allowing care teams to see progression earlier and intervene with better information.

Target use casePlaque psoriasis and longitudinal follow-up where symptoms, quality of life, and visual skin changes need to be monitored over time—not only at isolated clinic encounters.

Dermapy RPM approach

A psoriasis-specific remote monitoring loop.

Dermapy is structured around a clinically meaningful loop: collect remote data, make it visible to the clinician, and support timely clinical action when the patient’s status changes.

Patient reports outcomes

Patients complete scheduled ePROMs, including symptom burden and quality-of-life measures relevant to psoriasis follow-up.

Patient adds photos

Clinical images add visual context to inflammation and lesion changes that are difficult to capture in text alone.

Clinician reviews trends

Dermapy presents structured follow-up information so the clinician can review changes over time instead of isolated snapshots.

Clinician decides next step

Contact, advice, prioritisation, or treatment adjustment remains clinician-led. Dermapy supports the decision; it does not replace it.

What patients said

Remote monitoring can change how patients engage with their psoriasis care.

Patient feedback from the programme points to motivation, treatment consistency, and earlier awareness of worsening disease.

It has disciplined me to use skin creams, because I didn’t want to get “bad grades” on the symptom scores. It has been of great help.

It has given me additional motivation to take action against my disease.

Sometimes I get comfortable with my disease, but having to report it, is good to prevent large exacerbations.

Initially I was sceptical, but when the scores got worse and I received a call from my doctor, asking what happened, then it motivated me to be consistent with my treatment.

Selected patient feedback from the psoriasis remote monitoring programme.

Published and ongoing studies

Study portfolio for Dermapy in psoriasis.

Below is a concise research overview for scientific and reimbursement audiences, including published outputs and the current evidence-generation pathway.

PublishedJMIR · 2025

Remote Monitoring of Psoriasis: Comparing Care Models and Evaluating Quality of Life Outcomes

Study type: Mixed methods study comparing care models in psoriasis remote monitoring.

Specialist-care participants showed a significant mean DLQI reduction of −1.33 (P=.01), while the primary-care group showed a nonsignificant change of −0.34 (P=.36).
Patients in specialist care were reported to be 3.91× more likely to reach a clinically meaningful DLQI improvement.
Supports the case that care model and implementation context matter in psoriasis RPM outcomes.

Open article

PublishedJMIR Formative Research · 2026

Adherence to Psoriasis Remote Monitoring and Its Associations With Demographic, Clinical, and Health Care Use Characteristics

Study type: Multicenter observational study on adherence to psoriasis remote monitoring.

102 patients were included in adherence analysis.
Mean adherence ratio was 63.4%, supporting feasibility of repeated remote follow-up with ePROMs.
Demonstrates the practical sustainability of Dermapy-style psoriasis monitoring across care levels.

Open article

Evidence programme

Feasibility clinical trial and pre-reimbursement phase

Timeline: 2022–2023

Used to establish feasibility, usability, and early cost signals in a real-world care model.
Supports the pre-reimbursement evidence package.
Provides the foundation for later pivotal evaluation rather than being an isolated proof-of-concept.

Request study details

In progressRCT · 2025–2027

Pivotal clinical trial (RCT)

Current focus: reimbursement-grade evidence generation for psoriasis RPM.

Clinical equivalence target highlighted in the presentation: ±3.12 (90%, α=0.05).
Economic focus includes cost-effectiveness, with earlier analyses suggesting cost-savings signals for moderate-to-severe groups.
Status: ongoing in the evidence-generation pathway.

Request study details

Research, adoption and implementation

Discuss adoption and research in your health system.

Built in the Estonian healthcare ecosystem by Dermtest OÜ — the leading digital dermatology platform in Estonia, operating in Estonia and Germany.

Tallinn office

CEO Priit Kruus

Valukoja 10, 11415 Tallinn, Estonia

Telephone: +372 5561 2672

Email: priit.kruus@dermtest.com

Berlin office

Scharnhorststrasse 24, 10115 Berlin, Germany

Telephone: +49 152 14085520

Email: support@dermtest.de

Discuss science and adoption Dermapy on LinkedIn